Compare NEXA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | XERS |
|---|---|---|
| Founded | 1956 | 2005 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2017 | 2021 |
| Metric | NEXA | XERS |
|---|---|---|
| Price | $12.09 | $10.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $14.04 | $12.86 |
| AVG Volume (30 Days) | 491.4K | ★ 2.4M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $25.37 | $32.91 |
| Revenue Next Year | N/A | $23.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $5.05 | $5.25 |
| 52 Week High | $16.89 | $11.42 |
| Indicator | NEXA | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 65.16 |
| Support Level | $11.79 | $5.90 |
| Resistance Level | $14.98 | N/A |
| Average True Range (ATR) | 0.44 | 0.50 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 7.43 | 76.05 |
Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.